Factory Supply Raw Material Tideglusib Powder API CAS 865854-05-3 Tideglusib

• Customization: Available
• Powder: Yes
• Customized: Customized
• Model NO.: A37
• Certification: GMP, HSE, ISO 9001, USP, BP
• Suitable for: Adult
• State: Powder
• Purity: >99%
• Name: Tideglusib
• Appearance: White Powder
• Assay: 99%
• CAS: 865854-05-3
• OEM: Available
• Sample: Available
• Suitable: Adult
• Function: Anti-Inflammatory
• Transport Package: Foil Bag
• Specification: 99
• Trademark: /
• Origin: China
• Production Capacity: 10000 Kgs Per Month

Product Description

Product Name	Tideglusib	Other Name	4-Benzyl-2-(naphthalen-1-yl)-[1,2,4]thiadiazolidine-3,5-dione
CAS No.	865854-05-3	Appearance	White powder
MF	C19H14N2O2S	MW	334.39
Specification	99%	Testing Method	HPLC

Tideglusib (NP-12, NP031112) is a potent, selective and irreversible small molecule non-ATP-competitive glycogen synthase kinase 3 (GSK-3) inhibitor.. Other GSK inhibitors. There are few classes of GSK-inhibitors, including lithium (Martinez et al., 2011), the small peptide L803mts10, and members of the thiazolidinedione family, containing non-competitive inhibitors of GSK-3, such as TDZD-8.Tideglusib is a GSK-3 inhibitor currently in phase II clinical trials for the treatment of Alzheimer disease and progressive supranuclear palsy.

 

1. Neurodegenerative Diseases: Tideglusib is primarily being investigated for the treatment of neurodegenerative disorders, specifically targeting Alzheimer's disease.

2. Cognitive Enhancement: It aims to improve cognitive function and memory impairment, common symptoms in patients with Alzheimer's and other forms of dementia.

3. Inhibiting GSK-3β: As a GSK-3β (glycogen synthase kinase-3 beta) inhibitor, tideglusib can potentially modulate pathological processes associated with tau phosphorylation, a hallmark of Alzheimer's disease.

1. GSK-3β Inhibition: Tideglusib selectively inhibits GSK-3β, a kinase involved in multiple cellular pathways, including those related to apoptosis, inflammation, and tau protein phosphorylation.

2. Tau Phosphorylation Regulation: By inhibiting GSK-3β, tideglusib regulates tau phosphorylation levels, helping to prevent the formation of neurotoxic tau aggregates that contribute to neuronal death in Alzheimer's disease.

3. Potential Neuroprotection: By modulating these pathways, tideglusib demonstrates neuroprotective effects, potentially slowing down the progression of neurodegeneration and preserving cognitive function.

4. Anti-Inflammatory Effects: GSK-3β inhibition has also been linked to reduced inflammation, another key factor in the pathogenesis of neurodegenerative diseases.